{"disease":{"id":"familial-chylomicronemia-syndrome-fcs","name":"familial chylomicronemia syndrome fcs"},"drugs":{"marketed":[{"drug_id":"plozasiran","indication_name":"familial chylomicronemia syndrome (FCS)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Redemplo","generic_name":"PLOZASIRAN","company_name":"Arrowhead","drug_phase":"marketed","molecular_target":"apoC-III mRNA","drug_class":"APOC-III-directed RNA Interaction [EPC]","quality_score":47,"revenue":null,"mechanism":"Plozasiran reduces hepatic and serum apoC-III protein by degrading apoC-III mRNA via RNA interference, leading to increased clearance of serum triglycerides."}],"pipeline":[],"offLabel":[],"totalMarketed":1,"totalPipeline":0},"trials":{"data":[],"total":0},"guidelines":[],"source":"Drug Landscape verified database"}